Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)

Basso, Umberto; Roma, Anna; Brunello, Antonella; Falci, Cristina; Fiduccia, Pasquale; Banzato, Alberto; Bononi, Antonio; Gusella, Milena; Vamvakas, L.; Zagonel, Vittorina; Monfardini, S.

doi:10.1016/j.jgo.2013.07.004

Cited by 19 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We do not report any case of severe cardiac toxicity. This is matching with previous studies published by Al-Batran et al [13], Keller et al [17], and Basso et al [28] and likely similar results of studies conducted by Harbeck et al [29] and Huober et al [20] who reported that the incidence of severe cardiac toxicity was about 1%. We recorded that PPE was the most common adverse effect (28% for all grades and 9% for grade 3/4 toxicities).…”

Section: Discussionsupporting

confidence: 92%

Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer

Khallaf¹,

Roshdy²,

Ibrahim³

2020

ABCR

View full text Add to dashboard Cite

Purpose: The treatment of advanced breast cancer (ABC) is still challenging aiming mainly to improve or maintain the quality of life. The efficacy of pegylated liposomal doxorubicin (PLD) was proven in patients with ABC. Because its expensive treatment there is a great need to find the predictive factors for the clinical outcome of PLD. Our purpose was to evaluate the factors which would affect the clinical outcomes in patients receiving PLD for advanced breast cancer. Methods: Retrospectively, we studied the medical records of 60 eligible patients during the period of seven years (Jan. 2011-Dec. 2017). All patients were treated in Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Egypt. We included only patients with visceral metastasis who received at least 2 cycles of PLD and had radiological assessment after that. Clinical benefit rate of PLD and survival outcome were assessed and correlated with patients and disease characteristic. Results: The majority of patients had a performance status grade II (81.7%), recurrent disease (86.7%), more than one metastatic site (83.3%), and chemoresistance to previous anthracycline (75%). The clinical benefit rate (CBR) to PDL was 30%. We found statistical significant association between higher CBR and biological subtypes (p < 0.001), type of metastatic breast disease (p = 0.003), chemosensitivity to anthracycline (p < 0.001), and the number of previous lines of chemotherapy (p = 0.041). The median progression-free survival (PFS) was five months. There was a statistically-significant improvement of PFS among patients with anthracycline-sensitive tumors compared to those with anthracycline-resistant tumors (10 months vs. 5 months, respectively, p = 0.004). The most common toxicity was palmar-plantar erythrodysesthesia (28% for all grade and 9% for grade 3 or more). There was no severe cardiotoxicity or treatment-related death.

show abstract

Section: Discussionsupporting

confidence: 92%

Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer

Khallaf¹,

Roshdy²,

Ibrahim³

2020

ABCR

View full text Add to dashboard Cite

show abstract

“…Although the trial showed that pegylated liposomal doxorubicin could have equivalent activity to doxorubicin with an improved toxicity profile, no further development of this drug has been planned for the elderly population with sarcoma, in contrast to older women with breast cancer 7 . Therefore, the optimal chemotherapy regimen for elderly patients, especially those considered to be unfit as defined using multidimensional geriatric assessment 8 , remains undefined.…”

Section: Introductionmentioning

confidence: 99%

Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline

Maruzzo

Brunello

Diminutto³

et al. 2016

Anti-Cancer Drugs

Self Cite

View full text Add to dashboard Cite

Systemic chemotherapy comprising anthracycline monotherapy is the standard regimen for metastatic soft tissue sarcomas, particularly leiomyosarcomas, which have limited sensitivity to ifosfamide. However, the optimal chemotherapy regimen for elderly patients, especially those considered unfit for anthracyclines, is undefined. Trabectedin is a potent marine-derived antineoplastic drug with documented activity in liposarcomas and leiomyosarcomas. It is registered in Europe for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. We report the long-term response to first-line trabectedin therapy in an elderly patient with metastatic leiomyosarcoma unfit for standard therapy. A 66-year-old woman underwent resection of a pelvic epithelioid leiomyosarcoma with positive margins in December 2002, followed by postoperative radiotherapy. In February 2012, she was diagnosed with multiple lung lesions and local relapse in the pelvis. As she was considered unsuitable for both anthracycline and ifosfamide because of cardiovascular comorbidities and because she was highly anxious at the prospect of developing alopecia, vomiting, and fatigue, we commenced treatment with trabectedin at 75% of the standard dose of 1.5 mg/m2 every 3 weeks. Treatment was well tolerated, and the patient continued treatment for 25 cycles, with disease stabilization according to the RECIST criteria and a partial response according to the Choi criteria. Disease progression was observed in November 2013 and the patient died 20 months after the diagnosis of metastases. Trabectedin may represent an alternative option for highly selected elderly patients with metastatic sarcoma and unfit for anthracyclines; careful monitoring of toxicities is strongly recommended.

show abstract

“…Thus, some studies have specially evaluated the role of a combined PLD regime in chemotherapy of elderly patients with breast cancer and adopted dosages similar to other clinical studies. Basso et al (2013) examined the therapeutic efficacy of PLD (administered at 20 mg/m 2 every two weeks) for elderly patients with advanced breast cancer, and all patients enrolled were older than 70 years, among whom the total effective rate was 33.3% and the average median time to tumor progression was 10.3 months. Observed III-IV grades toxic and side effects included a small amount of anemia, mocusal inflammation, infection, pulmonary embolism, but no cardiac toxicity.…”

Section: Elderly Patientsmentioning

confidence: 99%

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

Zhao

Ding

Shen

et al. 2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Breast cancer is one of the malignant tumors with the highest morbidity and mortality. It is helpful to reduce the rate of tumor recurrence and metastasis by treating breast cancer with adjuvant chemotherapy, so as to increase the cure rate or survival of patients. In recent years, liposomes have been regarded as a kind of new carrier for targeted drugs. Being effective for enhancing drug efficacy and reducing side effects, they have been widely used for developing anticancer drugs. As a kind of anthracycline with high anticancer activity, doxorubicin can treat or alleviate a variety of malignant tumors effectively when it is used on its own or in combination with other anticancer drugs. Although liposomal doxorubicin has been extensively used in the adjuvant chemotherapy of breast cancer, its exact therapeutic efficacy and side effects have not been definitely proven. Various clinical studies have adopted different combined regimes, dosages, and staging, so their findings differ to certain extent. This paper reviews the clinical application of liposomal doxorubicin in the adjuvant chemotherapy of breast cancer and illustrates therapeutic effects and side effects of pegylated liposomal doxorubicin (PLD) and non-PLD (NPLD) in clinical research, in order to discuss the strategies for applying these drugs in such adjuvant chemotherapy, looking forward to providing references for related research and clinical treatment in terms of dosage, staging, combined regimes, and analysis methods and so on.

show abstract

Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)

Cited by 19 publications

References 26 publications

Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer

Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer

Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

Contact Info

Product

Resources

About